Efficacy and tolerability of venlafaxine in the treatment of primary dysthymia

Journal of Psychiatry and Neuroscience

Volumn 23, Issue 5, 1998, Pages 288-292

  Ravindran, A V ^a   Charbonneau, Y ^a   Zaharia, M D ^b   Al Zaid, K ^a   Wiens, A ^a   Anisman, H ^a,b  

^a ROYAL OTTAWA HOSPITAL   (Canada)

^b CARLETON UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; NORADRENALIN UPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ADULT; AFFECTIVE NEUROSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DYSTHYMIA; FATIGUE; FEMALE; HUMAN; INSOMNIA; MALE; MENTAL DISEASE; NAUSEA; NEUROPHARMACOLOGY; ORAL DRUG ADMINISTRATION;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYCLOHEXANOLS; DYSTHYMIC DISORDER; FEMALE; HUMANS; MALE; PILOT PROJECTS; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS;

EID: 0032409013     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Howland RH. General health, health care utilization, and medical comorbidity in dysthymia. Int J Psychiatry Med 1993;23:211-38.
2. Weissman MM, Leaf PJ, Bruce ML, Florio L. The epidemiology of dysthymia in five communities: rates, risks, comorbidity, and treatment. Am J Psychiatry 1988;145:815-9.
3. Keller MB. The difficult depressed patient in perspective. J Clin Psychiatry 1993;54(2 Suppl):4-8.
4. Akiskal HS. Towards a definition of dysthymia: boundaries with personality and mood disorders. In: Burton SW, Akiskal HS, editors. Dysthymic disorders. London: Gaskel; 1990. p. 1-12.
5. Kocsis JH, Thase M, Koran L, Halbreich U, Yonkers K. Pharmacotherapy of pure dysthymia: sertraline vs. imipramine and placebo. Eur Neuropsychopharm 1994;(3 Suppl):S204.
6. Ravindran AV, Bialik RJ, Lapierre YD. Therapeutic efficacy of specific serotonin reuptake inhibitors (SSRIs) in dysthymia. Can J Psychiatry 1994;39:21-6.
7. Thase ME, Fava M, Halbreich U, Kocsis JH, Koran L, Davidson J, et al. A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia. Arch Gen Psychiatry 1996;53:777-84.
8. Ravindran AV, Hadrava V, Wiseman H. A multi-center double-blind placebo-controlled study of sertraline in the treatment of outpatients with dysthymia [abstract], Canadian Psychiatric Association 47th Annual Meeting; 1997; Calgary.
9. Morton WA, Sonne SC, Verga MA. Venlafaxine: structurally unique and novel antidepressant. Ann Pharmacother 1995;29: 387-94.
10. Muth EA, Haskins JT, Moyer JA, Husbands GE, Nielsen ST, Sigg EB. Anti-depressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol 1986;35:4493-7.
11. Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, et al. A comparison of venlafaxine, trazodone, and placebo in major depression. J Clin Psychopharmcol 1994;14:99-106.
12. Nierenberg AA, Feighner JP, Rudolph R, Cole JO, Sullivan J. Venlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol 1994;14:419-23.
13. Dunner DL, Hendrickson HE, Bea C, Budech CB. Venlafaxine in dysthymic disorder. J Clin Psychiatry 1997;58:528-31.
14. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychology 1967;6:278-98.
15. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychology 1959;32:50-5.
16. Stewart JW, McGrath PJ, Quitkin FM, Rabkin J, Harrison W, Wager S, et al. 1993. Chronic depression: response to placebo, imipramine, and phenelzine. J Clin Psychopharmacology 13:391-6.
17. Versiani M, Nardi D, Capponi R, Costa DA, Magistris H, Ucha Udabe R. Moclobemide compared with imipramine in the treatment of chronic depression (dysthymia DSM-III-R): a double-blind placebo-controlled trial. Clin Neuropharmacol 1992;15(1 Suppl):148b.
18. Ravindran AV, for the Venlafaxine XR Study Group. Efficacy and tolerability of once-daily venlafaxine XR versus fluoxetine in depressed outpatients with concomitant anxiety [abstract]. Canadian Psychiatric Association 47th Annual Meeting; 1997; Calgary.
19. Mendels J, Johnston R, Mattes J, Riesenberg R. Efficacy and safety of b.i.d. doses of venlafaxine in a dose-response study. Psychopharmacol Bull 1993;29:169-74.
20. Entsuah AR, Rudolph RL, Chitra R. Effectiveness of venlafaxine in a broad spectrum of depressed patients: a meta-analysis. Psychopharmacol Bull 1995;31:759-66.